Skip to main content

Research Repository

Advanced Search

Role of oral teriflunomide in the management of multiple sclerosis

Tanasescu, Radu; Evangelou, Nikos; Constantinescu, Cris S.

Role of oral teriflunomide in the management of multiple sclerosis Thumbnail


Authors

Radu Tanasescu

Nikos Evangelou

Cris S. Constantinescu



Abstract

The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed.

Citation

Tanasescu, R., Evangelou, N., & Constantinescu, C. S. (2013). Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 9, https://doi.org/10.2147/NDT.S31248

Journal Article Type Article
Publication Date Apr 22, 2013
Deposit Date Apr 28, 2014
Publicly Available Date Apr 28, 2014
Journal Neuropsychiatric Disease and Treatment
Print ISSN 1176-6328
Electronic ISSN 1178-2021
Publisher Dove Press
Peer Reviewed Peer Reviewed
Volume 9
DOI https://doi.org/10.2147/NDT.S31248
Public URL https://nottingham-repository.worktribe.com/output/714335
Publisher URL http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639219/

Files





Downloadable Citations